0001209191-23-054330.txt : 20231103
0001209191-23-054330.hdr.sgml : 20231103
20231103163252
ACCESSION NUMBER: 0001209191-23-054330
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231101
FILED AS OF DATE: 20231103
DATE AS OF CHANGE: 20231103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Novack David F
CENTRAL INDEX KEY: 0001573072
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34207
FILM NUMBER: 231376886
MAIL ADDRESS:
STREET 1: 39 YORKSHIRE DR
CITY: OAKLAND
STATE: CA
ZIP: 94618
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: DYNAVAX TECHNOLOGIES CORP
CENTRAL INDEX KEY: 0001029142
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330728374
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2100 POWELL STREET
STREET 2: SUITE 720
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: 5108485100
MAIL ADDRESS:
STREET 1: 2100 POWELL STREET
STREET 2: SUITE 720
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-11-01
0
0001029142
DYNAVAX TECHNOLOGIES CORP
DVAX
0001573072
Novack David F
C/O DYNAVAX TECHNOLOGIES
2100 POWELL STREET, SUITE 720
EMERYVILLE
CA
94608
0
1
0
0
President & COO
1
Common Stock
2023-11-01
4
M
0
20000
5.42
A
23187
D
Common Stock
2023-11-01
4
S
0
20000
14.12
D
3187
D
Stock Option (Right to Buy)
5.42
2023-11-01
4
M
0
20000
D
2027-02-11
Common Stock
20000
49000
D
The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on May 5, 2023.
This transaction was executed in multiple trades at prices ranging from $14.00 to $14.39; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax
This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 12, 2020, and one thirty-sixth (1/36) of the shares subject to the option vesting on the last day of each month thereafter.
Not applicable.
/s/ David Novack
2023-11-03